Intraoperative Radioluminescence Imaging for Real-Time Assessment of Targeted Cancer Resection

Author Name : Hidoc internal team

Oncology

Page Navigation

Abstract

Intraoperative radioluminescence imaging is an emerging surgical navigation technology designed to provide real-time information about the distribution of targeted radiopharmaceuticals during cancer resection. By detecting radiation emitted from tissues labeled with a tumor-directed agent, the method can help surgeons identify malignant deposits, define tumor boundaries, detect residual disease, and assess regional lymphatic or metastatic involvement during an operation. Its clinical value is particularly relevant when tumor margins are difficult to visualize with conventional inspection, palpation, fluoroscopy, or standard fluorescence imaging. The technology integrates molecular targeting with radiation detection, allowing surgical decision-making to be guided by biologic rather than purely anatomical information. Early clinical experience suggests potential benefits in prostate cancer, neuroendocrine tumors, gastrointestinal malignancies, and other cancers for which suitable radioligands are available. However, limitations include radiation safety requirements, variable tracer uptake, background activity, detector sensitivity, tissue penetration constraints, workflow integration, and the need for prospective evidence demonstrating improved oncologic outcomes. Intraoperative radioluminescence imaging should currently be viewed as an adjunct to established surgical, pathological, and imaging techniques rather than a replacement for them. Ongoing research is focused on optimizing radiopharmaceutical selection, detector design, quantitative interpretation, and integration with fluorescence, navigation, robotics, and artificial intelligence.

Introduction

Complete removal of malignant tissue while preserving normal anatomy is a central objective of oncologic surgery. Despite advances in cross-sectional imaging, image-guided intervention, minimally invasive techniques, and molecular oncology, surgeons may still encounter occult lesions, multifocal disease, infiltrative tumor margins, and anatomically complex sites in which visual discrimination is inadequate. Positive margins and unrecognized residual disease are associated with local recurrence, additional treatment, impaired quality of life, and worse long-term outcomes in several cancers. Intraoperative radioluminescence imaging addresses this challenge by translating preoperative molecular imaging information into an actionable intraoperative signal.

The approach generally requires administration of a radiopharmaceutical that binds a tumor-associated receptor, antigen, enzyme, or metabolic pathway. During surgery, a handheld or laparoscopic detector identifies photons or charged particles generated by radioactive decay in labeled tissue. Depending on the system, the surgeon may obtain point measurements, two-dimensional localization, or a radiation-sensitive image. The result is a form of molecular guidance that can complement direct visualization and conventional frozen-section assessment. Its relevance is greatest when the radiopharmaceutical has high tumor-to-background contrast and the target is expressed consistently throughout the disease.

Epidemiology / Disease Burden

The global burden of cancer continues to increase because of population aging, demographic growth, environmental exposures, and improved detection. Surgical resection remains a potentially curative treatment for many localized solid tumors, but the probability of incomplete resection varies according to tumor type, stage, anatomical location, biological aggressiveness, and surgical access. Margin involvement is particularly consequential in pancreatic, colorectal, head and neck, breast, sarcoma, brain, and pelvic malignancies, although the clinical meaning of a positive margin differs among diseases.

Conventional imaging may fail to identify small lesions, microscopic extension, or disease obscured by postoperative change and complex anatomy. In addition, some patients have discordant disease biology, with heterogeneous expression of the molecular target used for radioligand localization. The increasing use of targeted radiopharmaceuticals for diagnosis and therapy has created an opportunity to extend these agents into the operating room. Radioluminescence imaging may therefore be most useful in selected patients whose tumors demonstrate confirmed target expression on preoperative molecular imaging.

Pathophysiology

The biological foundation of the technique is selective accumulation of a radioactive tracer in malignant tissue. Targeted agents may bind prostate-specific membrane antigen, somatostatin receptors, fibroblast activation protein, carcinoembryonic antigen, or other disease-associated molecules. After administration, the agent circulates, undergoes receptor-mediated binding or internalization, and produces a measurable radiation signal from tissues with sufficient tracer concentration. The intensity of the signal depends on target density, blood flow, tracer pharmacokinetics, tumor perfusion, lesion size, tissue depth, and the physical properties of the radionuclide.

Radioluminescence systems use scintillating materials or related detector technologies to convert radiation into visible or quantifiable signals. The surgeon can compare suspected tissue with adjacent background tissue and use relative counts or signal intensity to support decisions about excision, additional sampling, or lymph-node evaluation. Unlike purely anatomical imaging, this process reflects the molecular phenotype of the tumor. Nevertheless, inflammation, benign hyperplasia, physiological uptake, urinary activity, and nonspecific retention can generate false-positive signals. Conversely, low target expression, necrosis, small-volume disease, or tissue attenuation can produce false-negative findings.

Risk Factors

The principal clinical risk factors relevant to incomplete resection are advanced local invasion, multifocal or infiltrative growth, close proximity to vital structures, recurrent disease, prior radiation or surgery, poorly defined tumor planes, and limited access during minimally invasive procedures. Tumor heterogeneity and variable target expression may also reduce the reliability of targeted imaging. From a procedural perspective, risks relate to radiation exposure, tracer administration, altered operative workflow, possible prolongation of anesthesia, and inappropriate reliance on an imaging signal without pathological confirmation.

Radiation exposure is generally planned within accepted diagnostic or therapeutic frameworks, but cumulative exposure should be considered in patients receiving repeated radiopharmaceutical studies. Staff protection requires adherence to institutional radiation-safety procedures, appropriate handling of contaminated materials, and coordination among nuclear medicine, surgery, medical physics, and pathology teams. Pregnancy, breastfeeding, renal impairment, allergy to formulation components, and clinically significant tracer-specific contraindications require individualized assessment.

Clinical Features

Because radioluminescence imaging is a procedural technology rather than a disease, its clinical application depends on the presentation of the underlying malignancy. Patients may have a primary tumor identified through symptoms, screening, biochemical testing, conventional imaging, or molecular imaging. The operative challenge may involve a solitary lesion, regional nodal disease, peritoneal deposits, recurrent tumor, or suspected residual disease after neoadjuvant treatment. The method is particularly relevant when the tumor is not readily distinguished from scar tissue, fibrotic tissue, blood, or normal parenchyma.

Diagnosis

Patient selection should begin with histopathological or cytological confirmation whenever feasible, followed by staging using guideline-concordant anatomical imaging and, where appropriate, molecular imaging. Preoperative radiopharmaceutical imaging establishes whether the tumor expresses the intended target, identifies disease distribution, and informs the timing of tracer administration. The expected biodistribution, urinary or hepatobiliary excretion, and normal-organ uptake should be reviewed before surgery.

Intraoperatively, radioluminescence findings should be interpreted alongside direct inspection, palpation, preoperative imaging, anatomical landmarks, and surgical judgment. Suspicious signals should be correlated with specimen orientation and, when clinically appropriate, frozen-section or permanent pathological analysis. A high signal is not equivalent to a diagnosis of viable cancer, and a low signal does not exclude microscopic disease. Standardized thresholds, signal-to-background ratios, and reporting terminology are needed to improve comparability among institutions and studies.

Treatment & Management

The technology is intended to support, not replace, oncologic surgical principles. Before incision, the multidisciplinary team should confirm the indication, tracer, administered activity, timing, target expression, detector availability, and contingency plan if the signal is inconclusive. During resection, the detector may be used to localize the primary lesion, identify additional deposits, guide lymph-node assessment, evaluate the wound bed, and screen the resected specimen for residual or multifocal disease.

Potential benefits include improved localization of small lesions, more confident margin assessment, reduction in unnecessary removal of normal tissue, detection of occult nodal or metastatic disease, and better documentation of the relationship between molecular imaging and surgical anatomy. In selected cases, these advantages could reduce reoperation and facilitate organ-preserving surgery. However, the method must not encourage excessive resection solely on the basis of nonspecific uptake. Decisions should remain consistent with tumor biology, anatomical safety, patient goals, and established standards for margin adequacy.

Recent Advances / Emerging Therapies

Recent development has focused on compact handheld detectors, laparoscopic probes, hybrid fluorescence-radioguided approaches, and systems capable of producing spatially resolved radiation images. Dual-labeled agents may provide both preoperative whole-body localization and intraoperative optical or radioluminescent guidance. This complementary strategy can combine the depth and sensitivity advantages of radioactive detection with the visual precision of fluorescence at the tissue surface.

Radioligand therapy is also stimulating interest in theranostic workflows in which the same molecular target is used for diagnosis, surgical guidance, and systemic treatment. Emerging targets such as fibroblast activation protein and tumor-specific antibodies may expand application beyond established receptor systems. Quantitative software, three-dimensional navigation, robotic integration, and machine-learning methods could assist with signal interpretation, although these tools require external validation and safeguards against algorithmic error.

Guideline Recommendations

At present, intraoperative radioluminescence imaging should be implemented within a multidisciplinary program and according to local regulations governing radiopharmaceutical use, radiation protection, informed consent, and surgical quality assurance. Patient selection should be based on a clinically meaningful surgical question and documented evidence that the tumor expresses the chosen molecular target. Institutions should establish protocols for tracer administration, operating-room coordination, detector calibration, contamination control, specimen handling, and pathological correlation.

Professional guidelines for the underlying cancer remain primary. Conventional staging, evidence-based resection principles, pathological margin assessment, and appropriate adjuvant treatment should not be omitted because intraoperative imaging is available. Clinicians should explain that the technique may improve lesion localization but cannot guarantee complete removal or eliminate the need for histopathology. Prospective registries and controlled trials should evaluate margin rates, recurrence, reoperation, complications, operative duration, patient-reported outcomes, cost-effectiveness, and overall survival.

Conclusion

Intraoperative radioluminescence imaging represents a clinically promising bridge between molecular imaging and precision cancer surgery. By providing real-time detection of targeted radioactive signals, it may improve identification of tumor deposits, guide tissue removal, and reveal disease that is difficult to recognize through conventional surgical assessment alone. Its greatest value is likely to occur in carefully selected patients with strong target expression and a clearly defined risk of occult or residual disease. Current limitations include biological heterogeneity, nonspecific uptake, attenuation, radiation-safety requirements, uncertain thresholds, and incomplete evidence for improved long-term outcomes. Accordingly, the technique should be integrated with established imaging, surgical judgment, and pathological evaluation. Continued multidisciplinary research and prospective clinical validation will determine whether radioluminescence imaging becomes a routine component of targeted oncologic surgery.

Featured News
Featured Articles
Featured Events
Featured KOL Videos

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot